Researchers from the National Institute of Technology Rourkela and the Indian Institute of Science Education and Research Berhampur have secured an Indian patent for a newly developed cotarnine-derived formulation being investigated for potential use against oral cancer.
The patent, titled “Design, Synthesis, and Formulation of a Cotarnine Derivative for Oral Cancer Therapy,” was granted on September 25, 2026. IISER Berhampur records the application number as 202531113686, filed on November 19, 2025 and published on December 12, 2025.
Interdisciplinary Research Brings Chemistry and Life Sciences Together
The work was carried out jointly by researchers from the Departments of Chemistry and Life Science at NIT Rourkela and the Department of Chemical Sciences at IISER Berhampur.
The research combines molecular design, chemical synthesis, formulation science and biological evaluation rather than examining the compound only as a laboratory chemical.
The objective was to develop a new derivative of cotarnine and examine whether it could serve as a candidate for further research into oral cancer therapy.
The inventors include Laxmipriya Prusty, Prof. Harekrushna Sahoo, Sruti Biswal and Prof. Bibekanand Mallick from NIT Rourkela, along with Pradyota Kumar Behera and Prof. Laxmidhar Rout from IISER Berhampur.
Cotarnine Derivative Shows Activity Against Oral Cancer Cells
According to the research team, the developed compound demonstrated anticancer activity against oral cancer cells during laboratory studies.
Researchers particularly reported activity against tongue cancer cells at low concentrations. The results have encouraged the team to pursue additional studies aimed at determining whether the compound can eventually progress towards therapeutic development.
Some reports identify the newly developed compound as S-27 and link the research to oral squamous cell carcinoma, one of the major forms of oral cancer.
Patent Protects the Formulation and Its Potential Healthcare Application
The intellectual property has been granted as Indian Patent No. 604125.
The patent covers the design, synthesis and formulation developed by the research team. Securing the patent establishes intellectual-property protection for the invention while scientific and preclinical development continues.
A patent does not mean the compound has been approved as a medicine. It confirms legal protection for the invention, not clinical effectiveness or regulatory approval.
More Testing Is Required Before Clinical Use
The researchers have clearly distinguished promising laboratory results from an approved cancer treatment.
Further preclinical validation, including animal studies, will be required before the formulation can move towards clinical evaluation. Safety, effective dosage, toxicity, stability and pharmacological behaviour will all need to be examined in detail before any possible use in patients.
The formulation therefore remains an experimental research candidate and should not presently be regarded as a treatment for oral cancer.
Why the Research Matters for Oral Cancer Studies
Oral cancer remains an important area of medical research in India, creating demand for new molecular candidates that can eventually complement or improve existing treatment approaches.
Medicinal chemistry programmes such as this one attempt to modify chemical structures to improve biological activity while simultaneously developing formulations capable of delivering the candidate compound effectively.
By combining chemistry expertise at IISER Berhampur with chemistry and life-science capabilities at NIT Rourkela, the project illustrates how multidisciplinary academic research can move from molecular design towards biological testing and intellectual-property protection.
From Patent to Preclinical Research
The next major stage will be to establish how the cotarnine derivative behaves in more complex biological systems.
Preclinical research will need to determine its toxicity profile, mechanism of action, stability, pharmacokinetics and effectiveness in appropriate disease models. Only after satisfactory results at these stages could clinical evaluation in humans be considered.
The patent therefore marks the beginning of a longer translational pathway rather than its conclusion.
The NIT Rourkela–IISER Berhampur collaboration demonstrates how Indian academic institutions are increasingly taking laboratory discoveries beyond publication and towards protected technologies with potential healthcare applications. With the patent now secured, the cotarnine-derived formulation can proceed into the deeper validation required to determine its eventual therapeutic potential.
References
IISER Berhampur — Prof. Laxmidhar Rout research profile and collaborative patent details for Design, Synthesis, and Formulation of a Cotarnine Derivative for Oral Cancer Therapy.
https://www.iiserbpr.ac.in/people/profile/ldrout
Prameya News — Report on the NIT Rourkela–IISER Berhampur cotarnine-derived oral cancer research.
https://www.prameyanews.com/nit-rourkela-develops-cotarnine-derivative-for-oral-cancer
The Hans India — Report on the patented formulation and oral cancer research.
https://www.thehansindia.com/odisha/iiser-nit-patent-advances-oral-cancer-therapy-1127184
You may also like
-
Ayurveda and the Main Meal: Why Midday Matters
-
Robotics, AI and Nanoscience Set to Transform Precision Medicine in India
-
Why Ayurveda Recommends Eating Only When Hungry
-
Ayurveda on Eating at the Right Time: How Food Timing Supports Balance and Health
-
Ayurveda and Late-Night Living: What Irregular Sleep Does to the Body
